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Abstract 31 
The putative cache (Ca2+ channel and chemotaxis receptor) domain containing 1 (CACHD1) 32 
protein has predicted structural similarities to members of the D2G voltage-gated Ca2+ channel 33 
(VGCC) auxiliary subunit family. CACHD1 mRNA and protein were highly expressed in the 34 
male mammalian CNS, in particular in the thalamus, hippocampus and cerebellum, with a 35 
broadly similar tissue distribution to CaV3 subunits, in particular, CaV3.1. In expression 36 
studies, CACHD1 increased cell-surface localization of CaV3.1 and these proteins were in 37 
close proximity at the cell surface consistent with the formation of CACHD1-CaV3.1 38 
complexes. In functional electrophysiological studies, co-expression of human CACHD1 39 
with CaV3.1, CaV3.2 and CaV3.3 caused a significant increase in peak current density and 40 
corresponding increases in maximal conductance. By contrast, D2G-1 had no effect on peak 41 
current density or maximal conductance in either CaV3.1, CaV3.2 or CaV3.3. Comparison of 42 
CACHD1-mediated increases in CaV3.1 current density and gating currents revealed an 43 
increase in channel open probability. In hippocampal neurons from male and female E19 rats, 44 
CACHD1 overexpression increased CaV3-mediated action potential (AP) firing frequency 45 
and neuronal excitability. These data suggest that CACHD1 is structurally an D2G-like 46 
protein that functionally modulates CaV3 voltage-gated calcium channel activity. 47 
 48 
49 
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Significance Statement 50 
This is the first study to characterise the CACHD1 protein. CACHD1 is widely expressed in 51 
the CNS, in particular in the thalamus, hippocampus and cerebellum. CACHD1 distribution 52 
is similar to that of low-voltage-activated (CaV3, T-type) calcium channels, in particular to 53 
CaV3.1, a protein which regulates neuronal excitability and is a potential therapeutic target in 54 
conditions such as epilepsy and pain. CACHD1 is structurally a D2G-like protein that 55 
functionally increases CaV3 calcium current. CACHD1 increases the presence of CaV3.1 at 56 
the cell surface, forms complexes with CaV3.1 at the cell-surface and causes an increase in 57 
channel open probability. In hippocampal neurons, CACHD1 causes increases in neuronal 58 
firing. Thus, CACHD1 represents a novel protein that modulates CaV3 activity. 59 
 60 
 61 
62 
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Introduction 63 
The putative CACHD1 gene was identified following a systematic search for proteins with 64 
structural homology to D2G VGCC auxiliary subunits. The human CACHD1 gene on 65 
chromosome 1p31.3 encodes the putative protein CACHD1 and has many orthologs, 66 
including in speciation as early as C. elegans (tag-180) and D. melanogaster (CG16868) 67 
(Anantharaman and Aravind, 2000). Despite only a 13-16% gene homology and a <21% 68 
protein identity with the D2G VGCC auxiliary subunits, there are several key structural 69 
similarities between CACHD1 and D2G in terms of the arrangement of protein motifs. D2G 70 
and CaVE subunits are described as auxiliary or accessory VGCC subunits that modulate cell-71 
surface expression and biophysical properties of high-voltage-activated (HVA) CaV1 (L-type 72 
Ca2+ current) and CaV2 (P/Q, N- and R-type Ca2+ current) VGCC major D1 subunits 73 
(Dolphin, 2012; Dolphin, 2013). In particular, D2G subunits are proposed to associate with 74 
HVA channels within the secretory pathway to promote plasma membrane trafficking and, 75 
consequentially, to contribute to synaptic abundance (Dolphin, 2012), transmitter release 76 
(Hoppa et al., 2012) and to defining the extent of the active zone (Schneider et al., 2015). 77 
D2G-1 and D2G-2 represent molecular targets of gabapentinoid drugs (Dooley et al., 2007). 78 
However, modulation of low-voltage-activated (LVA) CaV3 family (T-type Ca2+ current) by 79 
existing D2G and CaVE auxiliary subunits has not been firmly established (Dolphin et al., 80 
1999; Lacinová et al., 1999; Dubel et al., 2004). LVA currents are activated by small 81 
depolarization to regulate excitability around the resting membrane potential and CaV3 82 
channels have been proposed as therapeutic targets in diseases such as epilepsy and pain 83 
(Perez-Reyes, 2003; Cheong and Shin, 2013; Powell et al., 2014; Snutch and Zamponi, 84 
2017); therefore, knowledge of proteins that modulate CaV3 activity is paramount. 85 
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Here, we investigate the novel CACHD1 protein and test the hypothesis that 86 
CACHD1 represents an D2G-like protein that modulates CaV3 channels. We have previously 87 
reported that, by contrast to D2G, the CACHD1 subunit has no clear effect on CaV2.2 88 
biophysical properties when co-expressed together with E2a in expression system studies 89 
(Soubrane et al., 2012). We characterise the expression of the CACHD1 gene in rat and 90 
human tissue at the transcriptional and translational level, and demonstrate that CACHD1, 91 
but not D2G-1, increases CaV3 (T-type) current density and maximal conductance. CACHD1 92 
increases CaV3.1 channel levels at the plasma membrane and data were consistent with 93 
CACHD1 forming complexes with CaV3.1 at the cell surface to increase channel open 94 
probability. We further demonstrate that CACHD1 expression causes a functional increase in 95 
T-type current-mediated excitability in hippocampal neurons. Together, these data 96 
demonstrate that CACHD1 is structurally an D2G-like protein which functionally modulates 97 
CaV3 activity. 98 
99 
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Materials and Methods 100 
 101 
RNA isolation and real-time polymerase chain reaction (PCR) 102 
Tissue samples were dissected from 5 adult male Wistar rats (Harlan, UK) following 103 
isofluorane overdose and cervical dislocation, according to Home Office Animals (Scientific 104 
procedures) Act 1986, UK. Total RNA was extracted using an RNeasy kit (Qiagen, UK) with 105 
an on-column DNase I treatment. Additional total RNA samples from AMS Biotechnology 106 
(Abingdon, UK) originated from human male donors aged 24-65. RNA (500 ng) was reverse-107 
transcribed and relative quantification of CACHD1 and D2G-1 transcripts was performed 108 
using SYBR green and custom-made validated primers. HPRT1 was used as housekeeping 109 
gene. Absolute quantification of CACHD1, D2G-1, -2, -3, CaV2.2 and CaV1, -2, -3 transcripts 110 
was evaluated using ‘Best Coverage’ Taqman probes (Applied Biosystems, UK) against a 111 
standard curve of plasmids containing human CACHD1 and a rat single stranded DNA 112 
standard curve. 113 
 114 
Sample preparation for in situ hybridization and immunohistochemistry 115 
Rat tissue was kindly donated by Dr Emilio Russo, University Magna Grecia of Catanzaro, 116 
Italy. Briefly, 6-month-old male rats were sacrificed by i.p. injection of pentobarbital (200 117 
mg/kg) according to ARRIVE guidelines and local ethical approval committee of the 118 
University of Catanzaro and perfused-fixed with 4% PFA in RNAse-free PBS, pH 7.3. Brain 119 
tissue was extracted, post-fixed overnight in 4% PFA in RNAse-free PBS and then 120 
cryoprotected in 30% sucrose. After being processed to wax (Tissue-tek VIP), 5 Pm 121 
horizontal plane brain slices were cut using a microtome (Leica, UK). 122 
 123 
 7 
 
In situ hybridization 124 
A CACHD1 probe consisting of a cocktail of short 10-20bp oligonucleotides spanning ~1kb 125 
was designed by ACDBio (USA) and in situ hybridization was performed on 5 Pm rat brain 126 
sections using a RNAscope 2.0 FFPE-Red kit. Positive (POLR2A) and negative (DapB) 127 
probes were run in parallel. 128 
 129 
Immunohistochemistry 130 
Chromogenic immunohistochemistry was performed using antigen retrieval in citrate buffer 131 
(Thermo, UK) for 10 min and 3,3`-diaminobenzidine (DAB) staining (ImmPACT, Vector 132 
Labs, UK), dehydrated and mounted with DPX. Rabbit anti-CACHD1 (1:500) (Abcam, UK 133 
Cat AB75141, RRID: AB_1310016) with horseradish peroxidase-coupled anti-rabbit IgG 134 
(ImmPRESS, Vector Labs, UK) was used to detect CACHD1 protein. Qualitative expression 135 
of mRNA was evaluated with a brightfield microscope according to colour intensity of 136 
labelled mRNA. 137 
 138 
Antibodies for biochemistry 139 
The following antibodies were used: mouse anti-HA.11 (Cambridge Bioscience, UK; clone 140 
16B12; Lot No. B220767, RRID: AB_10063630); rabbit anti-Na+/K+-ATPase (Novus 141 
Biologicals, Abingdon, UK; NB100-80005, Lot No. YH02206, RRID: AB_2063297); mouse 142 
anti-c-Myc (Sigma-Aldrich Cat# M4439, clone 9E10, Lot No. 087M4765V, RRID: 143 
AB_439694), rabbit anti-c-Myc (Sigma-Aldrich Cat# C3956, Lot No. 016M4762V, RRID: 144 
AB_439680), mouse anti-E-actin (Sigma-Aldrich Cat# A5441, Lot No. 028K4826, RRID: 145 
AB_476744) and rabbit anti-CACHD1 (Sigma-Aldrich Cat# AV49592, Lot No. QC22258, 146 
RRID: AB_1852421); goat anti-mouse or rabbit IgG coupled to horseradish peroxidase 147 
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(Stratech Scientific Limited, Newmarket, UK); donkey anti-mouse or rabbit coupled to 148 
AlexaFluor488, 555 or 647 (Invitrogen, Paisley, UK). Note: We experienced vial-to-vial 149 
variation with the rabbit anti-CACHD1 antibody for Western blotting during this study. 150 
Although both vials were from the same Lot No. and specifically recognised CACHD1, the 151 
vial used for Fig. 4D gave rise to more non-specific staining on HEK cell lysates than vial 152 
used for Fig. 4A.  153 
 154 
Vectors and vector construction 155 
The human CACHD1 construct was purchased from Origene (Rockville, MA, USA) and the 156 
truncated clone completed by PCR. The subsequent open reading frame was then subcloned 157 
into pcDNA5/FRT. An N-terminal Myc tag was inserted after the natural signal sequence 158 
between Ala35-Glu36 using standard PCR techniques. All constructs were sequenced to 159 
confirm identity. Construction of the vector pcDNA5/FRT-HA-CLR-Myc-RAMP1 has been 160 
described elsewhere (Cottrell et al., 2007). 161 
 162 
Cell maintenance and propagation 163 
HEK293 tsA201 (HEK) cells were cultured in DMEM (Invitrogen, UK) containing 10% fetal 164 
bovine serum (Biosera, UK) and maintained in 95% air, 5% CO2 at 37 °C.  165 
 166 
Cell-surface biotinylation 167 
HEK cells were transiently transfected in 6 well plates using 3 μg DNA (ratio 2:1, GFP-168 
CaV3.1-HA:CACHD1) using Lipofectamine2000 (3:8, DNA:Lipofectamine2000). HEK cells 169 
transfected with empty vector (vector control, VC), VC + Myc-CACHD1, GFP-CaV3.1-HA + 170 
VC or GFP-CaV3.1-HA + Myc-CACHD1 were washed (3x PBS), incubated with 0.3 mg/ml 171 
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EZ-Link™-Sulfo-NHS-Biotin (Pierce, USA) in PBS (1 h, 4°C), washed (3x PBS) and cells 172 
lysed in RIPA buffer (50 mMTris/HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 173 
10 mM NaF, 10 mM Na4P2O7, 0.1 mM Na3VO4, 0.5% Nonidet P-40, peptidase inhibitor 174 
cocktail (Roche, UK)), and centrifuged. Biotinylated proteins were recovered by incubation 175 
with NeutrAvidin-agarose (30 μl, overnight, 4°C), pelleted, washed with RIPA buffer (3x 1 176 
ml), boiled in Laemmli buffer and analyzed by SDS-PAGE and Western blotting. 177 
 178 
SDS-PAGE and Western blotting 179 
Immunoprecipitations and whole cell lysates were separated by SDS-PAGE (6-9% 180 
acrylamide), proteins transferred to PVDF membranes (Immobilon-P, Millipore, UK) and 181 
blocked for 1 h at room temperature (1x PBS, 0.1% Tween20, 5% non-fat milk powder 182 
[blocking buffer]). Membranes were incubated with antibodies to HA (1:5,000), E-actin 183 
(1:20,000), CACHD1 (1:1000), rabbit or mouse Myc (1:5000) or Na+-K+-ATPase (1:20,000) 184 
(overnight, 4°C; blocking buffer). Membranes were washed for 30 min (1x PBS, 0.1% 185 
Tween20) and incubated with appropriate secondary antibodies coupled to horseradish 186 
peroxidase (1:10,000, 1 h, room temperature; blocking buffer). Immunoreactive proteins were 187 
detected using enhanced chemiluminescence (BioRad, UK). Densitometric analysis was 188 
performed using an ImageQuant-RT ECL imaging system (GE Healthcare, Chalfont St Giles, 189 
UK) and analysed using ImageQuant TL software. 190 
 191 
Immunofluorescent detection of cell-surface proteins 192 
HEK cells were transiently transfected in 12 well plates using 1 μg DNA (ratio 2:1, GFP-193 
CaV3.1-HA:Myc-CACHD1) using polyethylenimine (PEI; 1:2, DNA:PEI). HEK cells 194 
transfected with empty vector (vector control, VC), VC + Myc-CACHD1, GFP-CaV3.1-HA + 195 
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VC, GFP-CaV3.1-HA + Myc-CACHD1 or CLR•RAMP1 seeded onto coverslips and used for 196 
experimentation after 48 h. Cells were washed twice with PBSCM, incubated in DMEM 197 
containing 0.1% BSA and mouse anti-HA (1:100) and rabbit anti-c-Myc (1:500) antibodies 198 
(1 h, 4°C), washed twice again with PBSCM and then fixed in 100 mM PBS containing 4% 199 
paraformaldehyde (w/v), pH 7.4 (20 min, 4ºC). Coverslips were incubated in blocking buffer 200 
(1x PBS, 2% normal horse serum, 0.1% saponin) (30 min, room temperature (RT)) and then 201 
incubated with appropriate secondary antibodies (1:2000, 2 h, RT). Coverslips were washed 202 
(blocking buffer, 30 min, RT) and mounted using Vectashield containing DAPI. 203 
 204 
Proximity ligation assays 205 
HEK cells were transiently transfected in 12 well plates using 1 μg DNA (ratio 2:1, GFP-206 
CaV3.1-HA:Myc-CACHD1) using polyethylenimine (PEI; 1:2, DNA:PEI). HEK cells 207 
transfected with empty vector (vector control, VC), VC + Myc-CACHD1, GFP-CaV3.1-HA + 208 
VC, GFP-CaV3.1-HA + Myc-CACHD1 or CLR•RAMP1 seeded onto coverslips and used for 209 
experimentation after 48 h. Cells were washed twice with PBSCM, incubated in DMEM 210 
containing 0.1% BSA and mouse anti-HA (1:100) and rabbit anti-c-Myc (1:500) antibodies 211 
(1 h, 4°C), washed twice again with PBSCM and then fixed in 100 mM PBS containing 4% 212 
paraformaldehyde (w/v), pH 7.4 (20 min, 4ºC). After washing with PBSCM the proximity 213 
ligation assay was conducted according to the manufacturer’s instructions (Duolink® In Situ 214 
Red Starter Kit Mouse/Rabbit, Cat No. DUO92101, Sigma). Briefly, cells were blocked (1 h, 215 
37ºC), washed twice (5 min, room temperature) and then incubated with appropriate 216 
secondary antibodies (1 h, 37ºC). After washing (2x 5 min, room temperature), the ligation 217 
was conducted (30 min, 37°C) and the cells were washed twice more. Coverslips were then 218 
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incubated with the amplification reaction mixture (100 min, 37°C), washed and coverslips 219 
mounted in medium containing DAPI.  220 
 221 
Confocal microscopy 222 
Cells were observed with a Nikon Eclipse Ti laser-scanning confocal microscope using a 223 
100x/1.45 Oil DIC N2 objective. Images were collected at a zoom of 1-2 and at least five 224 
optical sections were taken at intervals of 0.5 μm. Single sections are shown. Images were 225 
processed using Adobe Photoshop and the NIS-Elements AR software. 226 
 227 
Transformed human embryonic kidney cell culture and transfection for 228 
electrophysiology 229 
For electrophysiology experiments, HEK cells were transfected using 4 Pl Fugene6 230 
(Promega, UK) with total 2 Pg pcDNA3 at 50:1:25 for CaV3.1/pmaxGFP, CaV3.2/pmaxGFP 231 
or CaV3.3/pmaxGFP with or without D2G-1 or CACHD1. Empty vector was used to 232 
compensate when D2G or CACHD1 was omitted. Cells were maintained at 95% air, 5% CO2 233 
at 37 °C and used for experimentation 24-48 h post transfection. 234 
 235 
Hippocampal neuron culture and transfection 236 
Low-density hippocampal cultures were prepared from male and female E19 rat embryos as 237 
described previously (Zhang et al., 2003). All experiments were carried out in compliance 238 
with the Guide for the Care and Use of Laboratory Animals of the National Institutes of 239 
Health and approved by the University of Virginia Animal Care and Use Committee and 240 
adhered to ARRIVE guidelines. Neurons were plated onto poly-L-lysine coated glass 241 
coverslips at a density of ~70 cells/mm2 and were transfected using lipofectamine 2000 at a 242 
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ratio of 2 μl lipofectamine 2000 per 1 μg DNA. Neurons were transfected with either 243 
CACHD1 or pcDNA3.1 at a ratio of 10׷1 excess to mVenus and moved 24 h after 244 
transfection to a new glia-feeder layer. 245 
 246 
Electrophysiology 247 
Recordings from HEK cells were made as described previously (Vogl et al., 2015). Current-248 
voltage (I-V) relationships from individual cells were fitted with a modified Boltzmann 249 
equation: I = Gmax x(V-Vrev) / (1 + exp (-(V - V1/2)/k)) where, Gmax is the maximal 250 
conductance (nS/pF), V1/2 is the midpoint of activation i.e. the voltage at which 50% of the 251 
channels are open, Vrev is the null potential and k is the slope factor. Tail currents (measured 252 
at -120 mV) were normalised to the maximal and minimal conductance and the resultant 253 
curves were fitted with following Boltzmann function: I=I0+((Imax-I0)/(1+exp(V1/2-V)/k))). 254 
Throughout, all comparative electrophysiological experiments were performed in 255 
transfection-matched cultures. 256 
Recordings from hippocampal neurons were performed as described previously 257 
(Jones et al., 2007). Throughout, data are expressed as mean S.E.M.  Methods to estimate the 258 
probability of channel opening, Po have been previously described by us (Shcheglovitov et 259 
al., 2008), which assumes no change in single channel current, reducing the relationship 260 
between whole-cell current (I) to I ≈ NPo, where N is the number of channels in a cell and Po 261 
is the probability of channel opening. N is estimated by measuring the channel gating current 262 
at the reversal potential for ionic current. The peak current represents the maximal gating 263 
charge Qmax, and is proportional to N. Peak ionic current conductance, Gmax, was determined 264 
by fitting the I–V curve, obtained from the same cell, with a Boltzmann-Ohm equation as 265 
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described earlier. Gmax is used as a proxy for I since it is not affected by changes in driving 266 
force. Therefore, the Gmax/Qmax ratio can be used to estimate Po. 267 
 268 
Experimental Design and Statistical Analysis 269 
Throughout, all animal studies comply to appropriate ARRIVE and NIH guidelines and 270 
comply to country and institute guidelines (as specified in Methods section for each animal 271 
study). Details of animal strain, sex and method of sacrifice and use of anaesthetics are also 272 
stated in Methods section for each animal study. 273 
 274 
Throughout, all comparative biochemical and electrophysiological experiments were 275 
performed against transfection-matched culture controls. For electrophysiological 276 
experiments in recombinant cells, a minimum of 5 separate transfections were performed and 277 
numbers of individual replications are specified in appropriate Table. In all cases, sample size 278 
is stated in text, Figure legend or appropriate Table. Data subjected to statistical comparisons 279 
were assessed for assumptions of normality using a D’Agostino-Pearson omnibus test and 280 
expressed as mean ± standard error of the mean (SEM) throughout. Groups were compared 281 
by two-tailed paired or unpaired Student’s t-test, Mann-Whitney test, one- or two-way 282 
ANOVA tests followed by Bonferroni post-hoc tests, Kruskal-Wallis test and Dunn’s 283 
multiple comparison test or least squares fits compared using extra sum of squares F test as 284 
appropriate, using GraphPad Prism. In all cases, the statistical test used is stated in text, 285 
Figure legend or appropriate Table. Throughout, P<0.05 was taken as statistically significant 286 
and where appropriate values of P<0.01 and P<0.001 are specified. 287 
 288 
 289 
290 
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Results 291 
The novel CACHD1 protein is an D2G paralog  292 
We first investigated the predicted protein domain structure of CACHD1. Figure 1A 293 
illustrates that, like D2G-1, CACHD1 has a predicted exofacial N-terminus according to its 294 
signal sequence, a von Willebrand factor A (VWA) domain, two bacterial chemosensory-like 295 
cache domains and a short hydrophobic transmembrane domain followed by an intracellular 296 
C-terminus. Although CACHD1 and D2G share limited amino acid sequence homology 297 
(<21%), the similarities in modular domain content and arrangement between the proteins 298 
suggested the possibility that CACHD1 represents an D2G-like protein. However, there are 299 
also a number of differences between CACHD1 and D2G-1; these include: (i) D2G proteins 300 
are a single gene product which is post-translationally cleaved by proteases into D2 and 301 
Gcomponents and then associate via disulphide bonding (Calderon-Rivera et al., 2012; 302 
Segura et al., 2017); an important 6 amino acid motif for proteolytic cleavage has been 303 
identified (Andrade et al., 2007) which is absent in CACHD1. (ii) CACHD1 has a single 304 
predicted post-translational N-glycosylation site, whilst D2G-1 is heavily glycosylated at 305 
multiple potential sites (Douglas et al., 2006). (iii) CACHD1 has a variant RSR amino acid 306 
sequence at the binding site for gabapentinoids. (iv) Despite expressing a VWA domain, the 307 
functionally important MIDAS motif in CACHD1 (DxGxS) is different from that of D2G-1 308 
(DxSxS). (v) D2Gs have a predicted GPI-anchoring site (Davies et al., 2010) which is absent 309 
in CACHD1, which instead has a predicted transmembrane domain and a larger intracellular 310 
C-terminus domain.  311 
 312 
CACHD1 is highly expressed in brain hippocampal and thalamic regions  313 
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To obtain comparative and quantitative data on CACHD1 mRNA expression, real-time PCR 314 
was performed on rat and human mRNA from different regions of the brain and peripheral 315 
tissue. Relative expression profiles of CACHD1 and D2G-1 transcripts in rat tissue showed 316 
high CACHD1 expression in thalamus, hippocampus and cerebellum, whilst D2G-1 transcript 317 
expression was prominent in cortex, hippocampus and also, superior cervical ganglia (Fig. 318 
1B). We further investigated the anatomical distribution of CACHD1 at the transcriptional 319 
and protein levels using in situ hybridization and immunohistochemistry in adult mammalian 320 
brain. Rat brain regions displaying high mRNA include the hippocampus, anterodorsal 321 
thalamic nucleus, reticular thalamic nucleus, cerebellum, subiculum, medial entorhinal cortex 322 
and zona incerta (Fig. 1-1; Fig. 1-2). Hippocampal CACHD1 mRNA staining was strong in 323 
the dentate gyrus, as well as the CA1 pyramidal cell layer; mRNA staining was less strong in 324 
CA3. There was strong correlation between the levels of expression of CACHD1 mRNA and 325 
protein in rat brain (Fig. 1-2). In the thalamus, CACHD1 protein showed differential 326 
expression between major thalamic nuclei, in particular with prominent staining in the 327 
anterodorsal and reticular nuclei (Fig. 2). In human tissue, CACHD1 transcripts were 328 
similarly high in hippocampus, thalamus, and cerebellum (Fig. 2-1). CACHD1 transcript 329 
distribution was broadly similar to certain CaV3 subtypes, in particular to CaV3.1 (Fig. 2-1, 330 
Talley et al., 1999). CACHD1 transcript expression showed a differential distribution to D2G-331 
1 and D2G-2 subtypes and was most similar to D2G-3 (Fig. 2-1, Cole et al., 2005). In human 332 
tissue, CACHD1 protein levels were most abundant in dentate gyrus granule cells and 333 
pyramidal cells of the hippocampus cornus ammonis, cortical regions and thalamus, in both 334 
large diameter and small diameter cells (Fig. 3). 335 
 336 
CACHD1 promotes cell-surface expression of CaV3.1 337 
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Our expression data indicated high levels of CACHD1 expression in the thalamus, 338 
hippocampus and cerebellum. As expression levels of CaV3 subunits are also high in the 339 
thalamus and hippocampus, we hypothesized that CACHD1 may modulate CaV3 subunits in 340 
a recombinant HEK cell system. As a first step, we expressed CACHD1 in HEK cells and 341 
confirmed the specificity of the CACHD1 antibody (Fig. 4A). Immunoreactive CACHD1 was 342 
detected at approximately 170 kDa. We also confirmed that CACHD1 is present at the cell-343 
surface of HEK cells (Fig. 4B). Next, we determined if expression of CACHD1 affected the 344 
subcellular localization of CaV3.1 using a cell-surface biotinylation assay. Cell-surface 345 
proteins from HEK cells expressing empty vector, empty vector + CACHD1, GFP-CaV3.1-346 
HA + empty vector and GFP-CaV3.1-HA + CACHD1 were extracted and levels of GFP-347 
CaV3.1-HA analysed by Western blotting. Our data show that co-expression of CACHD1 348 
increased cell-surface localization of GFP-CaV3.1-HA (2.65 r 0.40 fold over control P<0.05 349 
two-tailed paired Student’s t-test; Fig. 4C). We also quantified the whole-cell expression of 350 
GFP-CaV3.1-HA in the same HEK cells, normalising to levels to E-actin (Fig. 4D). 351 
Importantly, our data shows that CACHD1 increases levels of GFP-CaV3.1-HA at the cell-352 
surface without affecting the total cellular level. 353 
 354 
CACHD1 and CaV3.1 are in close proximity at the cell-surface 355 
To determine if CaV3.1 and CACHD1 are present in a complex at the cell-surface, an epitope-356 
tagged CACHD1 (Myc-CACHD1) was used to aid cell-surface precipitation and detection. 357 
First, we tested the expression of the tagged protein and examined the ability of an anti-Myc 358 
antibody to bind to CACHD1 at the cell-surface. Myc-CACHD1 was expressed in HEK cell 359 
with a similar molecular mass (~170 kDa) to untagged CACHD1 (Fig. 5-1). Furthermore, we 360 
could detect Myc-CACHD1 at the cell-surface using immunofluorescence and confocal 361 
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microscopy (Fig. 5-1). Proximity ligation assays are commonly used to predict the likelihood 362 
that two proteins are sufficiently close enough to be present in the same complex. First, we 363 
determined if we could simultaneously detect Myc-CACHD1 and GFP-CaV3.1-HA at the 364 
cell-surface by confocal microscopy. Live HEK cells expressing empty vector, empty vector 365 
+ CACHD1, GFP-CaV3.1-HA + empty vector and GFP-CaV3.1-HA + CACHD1 were 366 
incubated with antibodies to the Myc and HA epitope tags of CACHD1 and CaV3.1, 367 
respectively and immunoreactive proteins visualized by immunofluorescence (Fig. 5A). No 368 
immunoreactive signals were detected in cells expressing empty vector, indicating antibody 369 
specificity. We were able to detect immunoreactive Myc signals only in cells expressing 370 
Myc-CACHD1. Similarly, we were able to detect signals for the HA antibody only in cells 371 
expressing GFP, indicating expression of GFP-CaV3.1-HA. We were also able to 372 
simultaneously detect CLR and RAMP1 at the cell-surface of transfected cells (Fig. 5A). 373 
Next, we labelled cells from the same transfections and performed a proximity ligation assay 374 
and visualized the cells using confocal microscopy. No PLA signals were detected in cells 375 
transfected with empty vector, empty vector + CACHD1, GFP-CaV3.1-HA + empty vector 376 
(Fig. 5B). By contrast, we could readily detect PLA signals in our positive control 377 
(CLR•RAMP1) and in transfected with GFP-CaV3.1-HA + CACHD1. Importantly, we could 378 
only detect PLA signals in cells expressing GFP (Fig. 5B). Thus, CACHD1 and CaV3.1 are in 379 
close proximity (<40 nm) at the cell-surface of HEK cells, indicating that they are likely in 380 
the same protein complex. As discussed more fully below, together, these data are consistent 381 
with CACHD1 increasing the cell-surface localization of CaV3.1 and with formation of 382 
CACHD1-CaV3.1 complexes at the cell surface. 383 
 384 
CACHD1 modulates recombinant CaV3 family VGCCs 385 
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We next tested the hypothesis that CACHD1 modulates T-type Ca2+ current. Co-expression 386 
of CACHD1 with CaV3.1 caused an increase in current density around peak values (Fig. 387 
6A,B) and a corresponding increase in maximal conductance (Fig. 6B inset; Table 1). By 388 
contrast, in our hands, CaV3.1 peak current and conductance was not modulated by D2G-1 in 389 
transfection-matched experiments (Fig. 6A,C; Table 1). CACHD1 effects were not 390 
accompanied by any overall change in the midpoint of activation or slope factor k (Table 1) 391 
and CACHD1 had no effect on CaV3.1 steady-state inactivation (data not shown). Neither 392 
CACHD1 nor D2G-1 affected CaV3.1 recovery from inactivation, as measured by lack of 393 
effect on mid-time of recovery from inactivation or Wrecovery (p>0.1 for both, one-way 394 
ANOVA with Bonferroni post-hoc test, data not shown).  395 
We next investigated potential modulation of CaV3.2 and CaV3.3 by CACHD1. Peak 396 
current density of CaV3.2 (Fig. 7A,C) and CaV3.3 (Fig. 7B,D) was increased by CACHD1 397 
with corresponding increases in maximal conductance (Table 1). CACHD1 had no significant 398 
effect on midpoint of activation or slope factor k for either CaV3.2 or CaV3.3 (Table 1) or 399 
steady-state inactivation (p>0.1, Kruskal-Wallis test with Dunn’s multiple comparison test, 400 
data not shown). CACHD1 was without effect on CaV3 activation or inactivation kinetics 401 
(Fig. 7-1; Table 1). In our hands, D2G-1 was without effect on current density in CaV3.2 (Fig. 402 
7E) or CaV3.3 (Fig. 7F). D2G-1 was without effect on CaV3.2 activation kinetics or on CaV3.2 403 
and CaV3.3 inactivation kinetics (Fig. 7-1; Table 1). D2G-1 had subtle effects on CaV3.1 404 
activation and inactivation kinetics and CaV3.3 activation kinetics (Fig. 7-1; Table 1). 405 
Overall, these data suggest that CACHD1, but not D2G-1, has a major effect on recombinant 406 
CaV3 VGCCs in terms of increased Ca2+ current density and maximal conductance. 407 
To determine the mechanism by which CACHD1 increased T-type channel currents, 408 
we estimated channel opening probability by measuring CaV3.1 gating currents at the reversal 409 
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potential for the ionic current (Fig. 8). In these experiments, the CACHD1-mediated increase 410 
in current density was recapitulated; thus, CaV3.1 maximal conductance 280 ± 30 pS/pF was 411 
significantly increased to 860 ± 15 pA/pF (n = 12 for each condition from 3 separate 412 
transfections; P<0.001 Mann-Whitney test) (data not shown). Measurement of area under the 413 
gating current provides a measure of the maximal gating charge Qmax. A plot of conductance 414 
versus gating current amplitude of the ionic current of the same cell provides a measure of 415 
open probability (Po) (Agler et al., 2005). Under these conditions, there was a ~1.4 fold 416 
increase in CaV3.1 Po in CACHD1 expressing cells (P<0.001, Fig. 8). These findings are 417 
consistent with CACHD1 interaction with CaV3.1 at the cell surface causing a functional 418 
increase in Po as a major contribution to CACHD1-mediated increases in Ca2+ current 419 
density. 420 
 421 
 422 
CACHD1 increase CaV3-mediated excitability in hippocampal neurons 423 
CaV3 channels are predicted to affect neuronal excitability around the resting membrane 424 
potential (Perez-Reyes, 2003; Cheong and Shin, 2013). To investigate the role of CACHD1 425 
in controlling neuronal excitability, we expressed CACHD1 (vs. empty vector controls) in 426 
hippocampal neurons. Transfected neurons were identified by co-expression of the biomarker 427 
mVenus (Fig. 9A). At a depolarizing current injection step of 220 pA, CACHD1 expressing 428 
neurons fired at a higher frequency than control neurons (Fig. 9B,C,D; Table 2). To further 429 
determine the role of T-type currents in establishing the increase in neuronal firing 430 
frequencies, we used the selective CaV3 channel blocker, TTA-P2 (Dreyfus et al., 2010). 431 
TTA-P2 (1 μM) reversed the firing frequency in CACHD1 expressing neurons back to 432 
control levels, but was without effect on control neurons (Fig. 9D; Table 2). To increase the 433 
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contribution of T-type current to neuronal excitability, a hyperpolarizing prepulse was used to 434 
recover LVA Ca2+ channels from inactivation, followed by a short depolarizing pulse to 435 
evoke an AP (Eckle et al., 2014). Under these conditions, CACHD1 expression caused a 436 
more profound increase in rebound firing frequency in CACHD1-transfected, but not control, 437 
neurons (Fig. 9E,F,G; Table 2). TTA-P2 (1 μM) reversed the increase in rebound AP firing 438 
in CACHD1 expressing neurons back to control levels, but was without effect on control 439 
neurons (Fig. 9G; Table 2). Throughout these experiments, CACHD1 had no significant 440 
effects on AP waveform properties (Fig. 9-1). These data support a CACHD1-mediated 441 
selective increase in T-type Ca2+ current, which leads to an increase in AP firing frequency 442 
and excitability in native neurons.443 
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Discussion 444 
This study characterises the protein CACHD1, encoded by the cache domain containing 1 445 
gene, and presents evidence that it represents a novel protein that modulates CaV3 VGCC 446 
activity. These data also provide further evidence that the major D2G-1 auxiliary calcium 447 
channel subunit does not fulfil a similar role for CaV3 channels. Detailed examination of 448 
CaV3.1 channels suggests an underlying mechanism whereby CACHD1 promotes increased 449 
CaV3.1 levels at the plasma membrane. In addition, data were consistent with CACHD1 450 
forming a complex with the channel at the cell surface to increase open probability and 451 
potentiate T-type current. 452 
 453 
CACHD1 protein modulates CaV3 VGCCs 454 
At a cellular level, CACHD1 transcripts were localised to granule and pyramidal cells of the 455 
hippocampus, and specific thalamic nuclei, notably the anterodorsal thalamic nucleus and 456 
reticular nucleus. Compared to the gene expression of the major D2G-1 and D2G-2 subunits, 457 
CACHD1 protein displayed a unique expression signature with, in particular, high expression 458 
in the thalamus and hippocampus and also in some regions of the cerebellum and cortex. 459 
CACHD1 was largely co-incident with the expression pattern of the CaV3.1 channel in the 460 
CNS (Talley et al., 1999). CACHD1 co-transfection with CaV3.1 in recombinant cells 461 
increased cell surface expression and Ca2+ current levels and maximal conductance. 462 
CACHD1 similarly modulated CaV3.2 and CaV3.3 current levels. Under equivalent 463 
conditions, D2G-1 was without significant effect on current levels in any CaV3 subtype. 464 
Proximity ligation assays were consistent with CACHD1 being able to form complexes with 465 
CaV3.1 at the cell surface. Mechanistically, CACHD1 effects on CaV3.1 were associated with 466 
increases in channel Po. A similar role has been reported for D2G auxiliary subunit 467 
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interactions with CaV1 channels; thus, D2G-1 increased channel Po and channel number as 468 
well as allosterically regulating drug binding (Shistik et al., 1995; Wei et al., 1995). Other 469 
studies have reported either an D2G-mediated reduction in Po (Wakamori et al., 1999) or a 470 
lack of effect on Po (Brodbeck et al., 2002). The latter study suggested that D2G 471 
predominantly performs a VGCC trafficking function to increase the number of active 472 
channels at the membrane (reviewed by Dolphin, 2012). The demonstrated CACHD1-473 
mediated increase in CaV3.1 cell surface expression is proposed to contribute to increase in 474 
cell Ca2+ current levels and maximal conductance. Here, the ~1.4-fold increase in Po is 475 
insufficient to fully account for the ~3 fold increase in current density seen in this set of 476 
experiments; channel number is predicted to increase (according to I= iNPo, where I is the 477 
whole-cell current, i is the single channel current (predicted to be constant) and N is the 478 
number of functional channels). Thus, increase in channel number may be attributable to 479 
either CACHD1-mediated increases in forward trafficking or reduced endocytosis of CaV3.1. 480 
With respect to α2δ auxiliary subunits, HVA CaVD1- α2δ interactions are reported to occur 481 
during early maturation at an intracellular site to drive forward trafficking to the plasma 482 
membrane (Cantí et al., 2005). Whilst CaV2.2 proteomic data have reported only a low 483 
appreciable amount of co-purified α2δ, with detection dependent on solubilising agent used 484 
(Müller et al., 2010), recent work using exofacial tags and antigen stripping techniques has 485 
supported α2δ also remaining associated with CaV2.2 at the plasma membrane (Cassidy et al., 486 
2014). In the present study, clear indication of CACHD1 and Cav3.1 complex formation at 487 
the cell surface was obtained using proximity ligand assays. Moreover, α2δ has the 488 
propensity to sequester into lipid raft compartments, as reported by us (Ronzitti et al., 2015) 489 
and others; this may also limit efficient detection of α2δ-CaVD1 complexes and it will be of 490 
interest to determine if CACHD1 similarly localizes to lipid rafts. Overall, we propose that 491 
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CACHD1 acts to increase CaV3 expression at the plasma membrane, at the cell surface 492 
CACHD1 can form a complex with the channel to increase Po and, consequentially, increase 493 
T-type current.  494 
 495 
Potential functional impact of CACHD1 on CaV3 VGCCs 496 
T-type Ca2+ currents are active around the resting membrane potential, where non-497 
inactivating channels generate low threshold Ca2+ spikes and the consequential triggering of 498 
Na+-dependant APs (Llinás 1988; Cheong and Shin, 2013). Of further interest here is that 499 
multiple mechanisms and proteins involved in folding and trafficking are reported to be 500 
involved in CaV3 expression at the cell surface. For example, proteins such the actin binding 501 
protein kelch-like 1 (Aromomolaran et al., 2010), stac1 (Rzhepetskyy et al., 2016) and 502 
calnexin (Proft et al., 2017) have a proposed role in CaV3 expression. Moreover, the 503 
glycosylated form of CaV3 represents the mature, correctly folded protein that is associated 504 
with higher Po (Weiss et al., 2013; Ondacova et al., 2016). T-type current has also been 505 
implicated in regulating presynaptic transmitter release in hippocampal and nociceptive 506 
circuitry (Huang et al., 2011; Jacus et al., 2012). Increases in CaV3 current are predicted to 507 
have profound effects on neuronal firing (McCormick and Huguenard, 1992). 508 
Correspondingly, over-expression of CACHD1 caused a pronounced increase in T-type 509 
current-mediated spike firing in hippocampal neurons. This activity was enhanced using a 510 
protocol to trigger recovery of CaV3 channels from their inactivated states, thereby increasing 511 
contribution of T-type current to neuronal excitability. CaV3 subtypes have been suggested as 512 
targets for anti-epileptic drugs (Powell et al., 2014). In models of temporal lobe epilepsy 513 
(TLE), selective up-regulation of T-type current in hippocampal neurons causes intrinsic 514 
bursting activity (Sanabria et al., 2001; Su et al., 2002). CaV3.2 transcripts were upregulated 515 
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in TLE models and intrinsic burst firing was reduced in CaV3.2 knock-out mice (Becker et 516 
al., 2008). Moreover, the deubiquitinating enzyme USP5 (Garcia-Callero et al., 2014), and 517 
preventing CaV3.2 deubiquitination was suggested to be beneficial in neuropathic and 518 
inflammatory pain. Our data suggest CACHD1 as a potential future target in 519 
hyperexcitability disorders associated with CaV3 dysfunction, such as epilepsy and pain. 520 
Moreover, CACHD1 gene expression has been shown to be modulated in patients with Type 521 
1 diabetes (Rassi et al., 2008) and Parkinson’s disease (Aguiar and Severino, 2010). 522 
 523 
CACHD1 protein structure dictates D2G-like function  524 
There are clear similarities in protein structural motifs between CACHD1 and D2G, namely, 525 
the presence of an N-terminal signal sequence, VWA and two downstream cache domains, 526 
these similarities suggest a conserved evolution (Anantharaman and Aravind, 2000). 527 
However, a number of important differences are also present. CACHD1 has a RSR variant at 528 
the gabapentin binding motif; whilst D2G-1 and D2G-2 were found to bind to gabapentinoids 529 
via their RRR binding motif, D2G-3 and D2G-4 have variant RNR sites which do not bind 530 
gabapentin (Wang et al., 1999; Marais et al., 2001). Earlier studies also identified porcine 531 
D2G-1 residues 516 to 537 within the first cache domain and residues 583 to 603 as also 532 
contributing to gabapentin binding (Wang et al., 1999). It will be of interest to determine if 533 
CACHD1 binds gabapentanoids. Despite sharing a common VWA domain, CACHD1 has a 534 
variant MIDAS motif. The D2G-1 MIDAS motif is functionally important in Ca2+ channel 535 
trafficking and synaptic function (Cantí et al., 2005; Hoppa et al., 2012). However, it has 536 
been suggested that MIDAS is unlikely to represent a key CaV2.2/D2G-1 interaction site, 537 
rather other regions are more likely involved (Cassidy et al., 2014); such regions may include 538 
cache domains, for example, rat D2G-1 residues 751-755, which are within a modelled cache 539 
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region, were implicated in CaV2.2/D2G-1 interaction (Cassidy et al., 2014). By contrast, 540 
comparative data investigating α2δ effects on CaV1.2 point to aspartate and the first serine 541 
residue within the DxSxS MIDAS site as molecular determinants for interaction and correct 542 
modulation of CaV1.2 (Briot et al., 2018). Of interest here is that CACHD1 contains a variant 543 
MIDAS with a glycine residue at the equivalent position of the critical serine residue 544 
identified by Briot et al. (2018). It has also been proposed that the D2G amino terminal 545 
(amino acids 26-230, termed the R-domain) contains all the machinery required to support 546 
D2G-1-mediated current enhancement in CaV2.2 channels (Song et al., 2015). This study 547 
identified a tryptophan residue (W205), which is conserved across all four D2G isoforms, as 548 
an important molecular determinant for these R-domain effects; it is of note that CACHD1 549 
also contains a conserved tryptophan residue at the equivalent position. 550 
In bacteria, the cache domain is proposed to arise from bacterial small molecule 551 
binding domains PAS and GAF (Anantharaman et al., 2001) and to play a key role in 552 
chemotaxis by acting as an extracellular receptor (Anantharaman and Aravind, 2000). Recent 553 
computational work has suggested that cache domains represent the dominant extracellular 554 
sensor in prokaryotes; by contrast, cache domains are largely limited to only D2G subunits in 555 
metazoa (Upadhyay et al., 2016). The present study adds CACHD1 to this classification. 556 
Whilst the functional relevance of mammalian cache domains remains to be fully established, 557 
deletions within the cache domain of D2G-4 have been associated with familial bipolar 558 
disorder (Van Den Bossche et al., 2010). Roles for ‘free’ D2G (not associated with VGCCs) 559 
have also been extended to functions including synaptogenesis and neurodegeneration via 560 
interaction with alternative ligands such as thrombospondins and prion proteins, respectively 561 
(Eroglu et al., 2009, Lana et al., 2016; Senatore et al., 2012); it will also be of interest to see 562 
if CACHD1 possesses similar functionality. 563 
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Overall, our data are consistent with CACHD1 structurally representing an D2G-like 564 
protein that act to increase CaV3 cell surface expression and current. Identification of the 565 
CACHD1 protein as a modulator of Cav3 activity expands the range of VGCC associated 566 
proteins and may provide an additional target itself, or via its modulation of T-type current, in 567 
different disease states. 568 
  569 
 27 
 
References 570 
Agler HL, Evans J, Tay LH, Anderson MJ, Colecraft HM, Yue DT (2005) G protein-gated 571 
inhibitory module of N-type (CaV2.2) Ca2+ channels. Neuron 46:891-904. 572 
 573 
Aguiar PM, Severino P (2010) Biomarkers in Parkinson Disease: global gene expression 574 
analysis in peripheral blood from patients with and without mutations in PARK2 and 575 
PARK8. Einstein (Sao Paulo) 8:291-297. 576 
 577 
Anantharaman V, Aravind L (2000) Cache - a signaling domain common to animal Ca2+-578 
channel subunits and a class of prokaryotic chemotaxis receptors. Trends Biochem Sci 579 
25:535-537. 580 
 581 
Anantharaman V, Koonin EV, Aravind L (2001) Regulatory potential, phyletic distribution 582 
and evolution of ancient, intracellular small-molecule-binding domains. J Mol Biol 307: 583 
1271-1292. 584 
 585 
Andrade A, Sandoval A, Oviedo N, De Waard M, Elias D, Felix R (2007) Proteolytic 586 
cleavage of the voltage-gated Ca2+ channel D2G subunit: structural and functional features. 587 
Eur J Neurosci 25:1705-1710.  588 
 589 
Aromolaran KA, Benzow KA, Cribbs LL, Koob MD, Piedras-Rentería ES (2010) T-type 590 
current modulation by the actin-binding protein Kelch-like 1. Am J Physiol Cell 591 
Physiol 298:C1353–1362. 592 
 593 
 28 
 
 594 
Baumgart JP, Vitko I, Bidaud I, Kondratskyi A, Lory P, Perez-Reyes E (2008) I-II loop 595 
structural determinants in the gating and surface expression of low voltage-activated calcium 596 
channels. PLoS ONE 3:e2976. 597 
 598 
Becker AJ, Pitsch J, Sochivko D, Opitz T, Staniek M, Chen CC, Campbell KP, Schoch S, 599 
Yaari Y, Beck H (2008) Transcriptional upregulation of Cav3.2 mediates epileptogenesis in 600 
the pilocarpine model of epilepsy. J Neurosci 28:13341-13353. 601 
 602 
Briot J, Mailhot O, Bourdin B, Tétreault MP, Najmanovich R, Parent L (2018) A three-way 603 
inter-molecular network accounts for the CaVα2δ1-induced functional modulation of the 604 
pore-forming CaV1.2 subunit. J Biol Chem Mar 27 [Epub ahead of print]. 605 
 606 
Brodbeck J, Davies A, Courtney JM, Meir A, Balaguero N, Cantí C, Moss FJ, Page KM, 607 
Pratt WS, Hunt SP, Barclay J, Rees M, Dolphin AC (2002) The ducky mutation in Cacna2d2 608 
results in altered Purkinje cell morphology and is associated with the expression of a 609 
truncated D2G2 protein with abnormal function. J Biol Chem 277:7684-7693. 610 
 611 
Calderon-Rivera A, Andrade A, Hernández-Hernández O, González-Ramírez R, Sandoval A, 612 
Rivera M, Gomora JC, Felix R (2012) Identification of a disulfide bridge essential for 613 
structure and function of the voltage-gated Ca2+ channel D2G-1 auxiliary subunit. Cell 614 
Calcium 51:22–30. 615 
 616 
 29 
 
Cantí C, Nieto-Rostro M, Foucault I, Heblich F, Wratten J, Richards MW, Hendrich J, 617 
Douglas L, Page KM, Davies A, Dolphin AC (2005) The metal-ion-dependent adhesion site 618 
in the Von Willebrand factor-A domain of D2G subunits is key to trafficking voltage-gated 619 
Ca2+ channels. Proc Natl Acad Sci U S A 102:11230-11235. 620 
 621 
Cassidy JS, Ferron L, Kadurin I, Pratt WS, Dolphin AC (2014) Functional exofacially tagged 622 
N-type calcium channels elucidate the interaction with auxiliary D2G-1 subunits. Proc Natl 623 
Acad Sci U S A 111: 8979-8984. 624 
 625 
Cheong E, Shin HS (2013) T-type Ca2+ channels in normal and abnormal brain functions. 626 
Physiol Rev 93:961-992. 627 
 628 
Cole R, Lechner SM, Williams ME, Prodanovich P, Bleicher L, Varney MA, Gu G (2005) 629 
Differential distribution of voltage-gated calcium channel alpha-2 delta (D2G) subunit 630 
mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. J Comp 631 
Neurol 491:246-269. 632 
 633 
Cottrell GS, Padilla B, Pikios S, Roosterman D, Steinhoff M, Grady EF, Bunnett NW (2007) 634 
Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying 635 
protein 1. J Biol Chem 282:12260-12271. 636 
 637 
Davies A, Kadurin I, Alvarez-Laviada A, Douglas L, Nieto-Rostro M, Bauer CS, Pratt WS, 638 
Dolphin AC (2010) The D2G subunits of voltage-gated calcium channels form GPI anchored 639 
 30 
 
proteins, a posttranslational modification essential for function. Proc Natl Acad Sci U S A 640 
107:1654–1659. 641 
 642 
Dolphin AC, Wyatt CN, Richards J, Beattie RE, Craig P, Lee JH, Cribbs LL, Volsen SG, 643 
Perez-Reyes E (1999) The effect of D2G and other accessory subunits on expression and 644 
properties of the calcium channel D1G. J Physiol 519:35-45. 645 
 646 
Dolphin AC (2012) Calcium channel auxiliary D2G and E subunits: trafficking and one step 647 
beyond. Nat Rev Neurosci 13:542-555. 648 
 649 
Dolphin AC (2013) The D2G subunits of voltage-gated calcium channels. Biochim Biophys 650 
Acta 1828:541-1549. 651 
 652 
Dooley DJ, Taylor CP, Donevan S, Feltner D (2007) Ca2+ channel D2G ligands: novel 653 
modulators of neurotransmission. Trends Pharmacol Sci 28:75-82. 654 
 655 
Douglas L, Davies A, Wratten J, Dolphin AC (2006) Do voltage-gated calcium channelD2G 656 
subunits require proteolytic processing into D2 and G to be functional? Biochem Soc Trans 657 
34:894-898. 658 
 659 
Dreyfus FM, Tscherter A, Errington AC, Renger JJ, Shin HS, Uebele VN, Crunelli V, 660 
Lambert RC, Leresche N (2010) Selective T-type calcium channel block in thalamic neurons 661 
reveals channel redundancy and physiological impact of ITwindow. J Neurosci 30:99-109.  662 
 663 
 31 
 
Dubel S, Altier C, Chaumont S, Lory P, Bourinet E, Nargeot J (2004) Plasma membrane 664 
expression of T-type calcium channel D1 subunits is modulated by high voltage-activated 665 
auxiliary subunits. J Biol Chem 279:29263-29269. 666 
 667 
Eckle V-S, Shcheglovitov A, Vitko I, Dey D, Yap CC, Winckler B, Perez-Reyes E (2014) 668 
Mechanisms by which a CACNA1H mutation found in epilepsy patients increases seizure 669 
susceptibility. J Physiol  592:795-809. 670 
 671 
Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, Chakraborty C, 672 
Mulinyawe SB, Annis DS, Huberman AD, Green EM, Lawler J, Dolmetsch R, Garcia KC, 673 
Smith SJ, Luo ZD, Rosenthal A, Mosher DF, Barres BA (2009) Gabapentin receptor D2G-1 is 674 
a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 675 
139:380-392. 676 
 677 
García-Caballero A,Gadotti VM, Stemkowski P, Weiss N, Souza IA, Hodgkinson V, Bladen 678 
C, Chen L, Hamid J, Pizzoccaro A, Deage M, François A, Bourinet E, Zamponi GW (2014) 679 
The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by 680 
enhancing Cav3.2 channel activity. Neuron 83:1144-1158.  681 
 682 
Hoppa M, Lana B, Margas W, Dolphin AC, Ryan TA (2012) D2G couples calcium channels 683 
to neurotransmitter release sites to control release probability. Nature 486:122–125. 684 
 685 
 32 
 
Huang Z, Lujan R, Kadurin I, Uebele VN, Renger JJ, Dolphin AC, Shah MM (2011) 686 
Presynaptic HCN1 channels regulate CaV3.2 activity and neurotransmission at select cortical 687 
synapses. Nat Neurosci 14:478-486. 688 
 689 
Jacus MO, Uebele VN, Renger JJ, Todorovic SM (2012) Presynaptic Cav3.2 channels 690 
regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci 32: 691 
9374-9382. 692 
 693 
Jones PJ, Wang Y, Smith MD, Hargus NJ, Eidam HS, White HS, Kapur J, Brown ML, Patel 694 
MK (2007) Hydroxyamide analogs of propofol exhibit state-dependent block of sodium 695 
channels in hippocampal neurons: implications for anticonvulsant activity J Pharmacol Exp 696 
Ther 320:828-36.  697 
 698 
Lacinová L, Klugbauer N, Hofmann F (1999) Absence of modulation of the expressed 699 
calcium channel D1G subunit by D2G subunits. J Physiol 516:639-645. 700 
 701 
Lana B, Page KM, Kadurin I, Ho S, Nieto-Rostro M, Dolphin AC (2016) Thrombospondin-4 702 
reduces binding affinity of [3H]-gabapentin to calcium-channel α2δ-1 subunit but does not 703 
interact with α2δ-1 on the cell-surface when co-expressed. Sci Rep 6:24531 704 
 705 
Llinás RR (1988) The intrinsic electrophysiological properties of mammalian neurons: 706 
insights into central nervous system function. Science 242:1654-1664. 707 
 708 
 33 
 
Marais E, Klugbauer N, Hofmann F (2001) Calcium channel D2G subunits-structure and 709 
gabapentin binding. Mol Pharmacol 59:1243-1248. 710 
 711 
McCormick DA, Huguenard JR (1992) A model of the electrophysiological properties of 712 
thalamocortical relay neurons. J Neurophysiol 68:1384-1400. 713 
 714 
Müller CS, Haupt A, Bildl W, Schindler J, Knaus HG, Meissner M, Rammner B, Striessnig J, 715 
Flockerzi V, Fakler B, Schulte U (2010) Quantitative proteomics of the Cav2 channel nano-716 
environments in the mammalian brain. Proc Natl Acad Sci U S A 107:14950-14957. 717 
 718 
Ondacova K, Karmazinova M, Lazniewska J, Weiss N, Lacinova L (2016) Modulation of 719 
Cav3.2 T-type calcium channel permeability by asparagine-linked glycosylation. Channels 720 
(Austin) 10:175–184. 721 
 722 
Perez-Reyes E (2003) Molecular physiology of low-voltage-activated T-type calcium channels. 723 
Physiol Rev 83:117-161. 724 
 725 
Powell KL, Cain SM, Snutch TP, O'Brien TJ (2014) Low threshold T-type calcium channels 726 
as targets for novel epilepsy treatments. Br J Clin Pharmacol 77:729-739. 727 
 728 
Proft J, Rzhepetskyy Y, Lazniewska J,  Zhang FX, Cain SM, Snutch TP, Zamponi G, Weiss 729 
N (2017) The Cacna1h mutation in the GAERS model of absence epilepsy enhances T-type 730 
Ca2+ currents by altering calnexin-dependent trafficking of CaV3.2 channels. Sci Rep 731 
7:11513. 732 
 34 
 
 733 
Rassi DM, Junta CM, Fachin AL, Sandrin-Garcia P, Mello S, Silva GL, Evangelista AF, 734 
Magalhães DA, Wastowski IJ, Crispim JO, Martelli-Palomino G, Fernandes AP, Deghaide 735 
NN, Foss-Freitas MC, Foss MC, Soares CP, Sakamoto-Hojo ET, Passos GA, Donadi EA 736 
(2008) Gene expression profiles stratified according to type 1 diabetes mellitus susceptibility 737 
regions. Ann N Y Acad Sci 1150:282-289.  738 
 739 
Ronzitti G, Bucci G, Emanuele M, Leo D, Sotnikova TD, Mus LV, Soubrane CH, Dallas 740 
ML, Thalhammer A, Cingolani LA, Mochida S, Gainetdinov RR, Stephens GJ, Chieregatti E 741 
(2014) Exogenous D-synuclein decreases raft partitioning of Cav2.2 channels inducing 742 
dopamine release. J Neurosci 34:10603-10615. 743 
 744 
Rzhepetskyy Y,  Lazniewska J, Proft J, Campiglio M,  Flucher BE, Weiss N (2016) A 745 
CaV3.2/Stac1 molecular complex controls T-type channel expression at the plasma 746 
membrane. Channels (Austin) 10:346–354. 747 
 748 
Sanabria ER, Su H, Yaari Y (2001) Initiation of network bursts by Ca2+-dependent intrinsic 749 
bursting in the rat pilocarpine model of temporal lobe epilepsy. J Physiol 532:205-216. 750 
 751 
Schneider R, Hosy E, Kohl J, Klueva J, Choquet D, Thomas U, Voigt A, Heine M (2015) 752 
Mobility of calcium channels in the presynaptic membrane. Neuron 86:672-679.  753 
 754 
 35 
 
Segura E, Bourdin B, Tétreault MP, Briot J, Allen BG, Mayer G, Parent L (2017) Proteolytic 755 
cleavage of the hydrophobic domain in the CaVα2δ1 subunit improves assembly and activity 756 
of cardiac CaV1.2 channels. J Biol Chem 292:11109-11124. 757 
 758 
Senatore A, Colleoni S, Verderio C, Restelli E, Morini R, Condliffe SB, Bertani I, Mantovani 759 
S, Canovi M, Micotti E, Forloni G, Dolphin AC, Matteoli M, Gobbi M, Chiesa R (2012) 760 
Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by 761 
impairing membrane delivery of VGCC D2G-1 subunit. Neuron 74:300-313. 762 
 763 
Shcheglovitov A, Vitko I, Bidaud I, Baumgart JP, Navarro-Gonzalez MF, Grayson TH, Lory 764 
P, Hill CE, Perez-Reyes E (2008) Alternative splicing within the I-II loop controls surface 765 
expression of T-type CaV3.1 calcium channels. FEBS Lett 582, 3765–3770. 766 
 767 
Shistik E, Ivanina T, Puri T, Hosey M, Dascal N (1995) Ca2+ current enhancement by D2/G 768 
and E subunits in Xenopus oocytes: contribution of changes in channel gating and D1 protein 769 
level. J Physiol 489:55-62. 770 
 771 
Snutch TP, Zamponi GW (2017) Recent advances in the development of T-type calcium 772 
channel blockers for pain intervention. Br J Pharmacol Jun 13 [Epub ahead of print]. 773 
 774 
Song L, Espinoza-Fuenzalida IA, Etheridge S, Jones OT, Fitzgerald EM (2015) The R-775 
domain: Identification of an N-terminal region of the D2G-1 subunit which is necessary and 776 
sufficient for its effects on CaV2.2 calcium currents. Curr Mol Pharmacol 8:169-179. 777 
 778 
 36 
 
 779 
Soubrane CH, Stevens EB, Stephens GJ (2012) Expression and functional studies of the 780 
novel CNS protein CACHD1. Physiology 2012 (Edinburgh) Proc Physiol Soc 27, PC74. 781 
 782 
Su H, Sochivko D, Becker A, Chen J, Jiang Y, Yaari Y, Beck H (2002) Upregulation of a T-783 
type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status 784 
epilepticus. J Neurosci 22:3645-3655. 785 
 786 
Talley E, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA (1999) Differential 787 
distribution of three members of a gene family encoding low voltage-activated (T-type) 788 
calcium channels. J Neurosci 19:1895-1911. 789 
 790 
Upadhyay AA, Fleetwood AD, Adebali O, Finn RD, IB ZN (2016) Cache domains that are 791 
homologous to, but different from PAS domains comprise the largest superfamily of 792 
extracellular sensors in prokaryotes. PLoS Comput Biol 12:e1004862. 793 
 794 
Van Den Bossche MJ, Strazisar M, De Bruyne S, Bervoets C, Lenaerts AS, De Zutter S, 795 
Nordin A, Norrback KF, Goossens D, De Rijk P, Green EK, Grozeva D, Mendlewicz J, 796 
Craddock N, Sabbe BG, Adolfsson R, Souery D, Del-Favero J (2012) Identification of a 797 
CACNA2D4 deletion in late onset bipolar disorder patients and implications for the 798 
involvement of voltage-dependent calcium channels in psychiatric disorders. Am J Med 799 
Genet B Neuropsychiatr Genet 159B:465-475. 800 
 801 
 37 
 
Vogl C, Tanifuji S, Danis B, Daniels V, Foerch P, Wolff C, Whalley BJ, Mochida S, 802 
Stephens GJ (2015) Synaptic vesicle glycoprotein 2A modulates vesicular release and 803 
calcium channel function at peripheral sympathetic synapses. Eur J Neurosci 41:398-409. 804 
 805 
Wakamori M, Mikala G, Mori Y (1999) Auxiliary subunits operate as a molecular switch in 806 
determining gating behaviour of the unitary N-type Ca2+ channel current in Xenopus oocytes. 807 
J Physiol 517:659-72. 808 
 809 
Wang M, Offord J, Oxender D, Su T (1999) Structural requirement of the calcium-channel 810 
subunit D2G for gabapentin binding. Biochem J 342:313-320. 811 
 812 
Wei X, Pan S, Lang W, Kim H, Schneider T, Perez-Reyes E, Birnbaumer L (1995) Molecular 813 
determinants of cardiac Ca2+ channel pharmacology. Subunit requirement for the high affinity 814 
and allosteric regulation of dihydropyridine binding. J Biol Chem 270:27106-27111. 815 
 816 
Weiss N, Black SA, Bladen C, Chen L, Zamponi GW (2013) Surface expression and function 817 
of Cav3.2 T-type calcium channels are controlled by asparagine-linked glycosylation. 818 
Pflugers Arch 465:1159-1170.  819 
 820 
Zhang H, Webb DJ, Asmussen H, Horwitz AF (2003) Synapse formation is regulated by the 821 
signaling adaptor GIT1. J Cell Biol 161:131-142. 822 
 823 
  824 
 38 
 
Figure Legends 825 
Figure 1. Predicted protein sequence homology and relative expression profile of 826 
CACHD1 and D2G-1. 827 
CACHD1 and D2G-1 subunits both contain a N-terminus signal peptide, a VWA domain, two 828 
cache domains, and transmembrane and intracellular domains. GBP: gabapentin binding 829 
domain (RRR). GBP*: gabapentin binding domain variant (RSR). MIDAS: metal-ion-830 
dependent adhesion site (DxSxS). MIDAS*: metal-ion-dependent adhesion site variant 831 
(DxGxS). VWA: von Willebrand factor A. Cache: Ca2+ channel and chemotaxis receptor. 832 
TM: transmembrane domain. Cys: cysteine. His: histidine (locations of domains are 833 
approximate and from data from www.Uniprot.org, figure drawn using DOG: Domain 834 
Graphics). (B) Relative expression profile of CACHD1 and D2G-1 mRNA in rat tissue 835 
determined using SYBR green real-time quantitative PCR and HPRT1 as housekeeping gene. 836 
DRG: dorsal root ganglion. SCG: superior cervical ganglion. (Data normalised to lowest 837 
tissue expression; n=3 experiments using 3 animals each). Figure 1 is supported by in situ 838 
hydridization data in different rat brain regions (Fig. 1-1) and qualitative expression profile of 839 
CACHD1 mRNA and protein in the adult rat brain (Fig. 1-2).  840 
 841 
Figure 2. CACHD1 protein expression in adult rat brain. 842 
Immunoreactive protein was detected using rabbit anti-CACHD1 with peroxidase anti-rabbit 843 
secondary antibody and DAB staining (brown). AD: anterodorsal thalamic nucleus; AVDM: 844 
anteroventral thalamic nucleus (dorsomedial); AVVL: anteroventral thalamic nucleus 845 
(ventro-lateral); fi: fimbria; MD: mediodorsal thalamic nucleus; Po: posterior thalamic 846 
nucleus; sm: strai medullaris; Rt: reticular thalamus nucleus; RtSt: reticular VL: ventrolateral 847 
thalamic nucleus; VPL: ventro-posterior lateral thalamus; g: granule cell layer; m: molecular 848 
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layer; p: Purkinje cell; wm: white matter. Figure 2 is supported by expression profiling of 849 
CACHD1 and different voltage-gated calcium channel subunit mRNA in human tissue (Fig. 850 
2-1). 851 
 852 
Figure 3. CACHD1 protein expression in human brain. 853 
Immunohistochemistry of adult human brain using rabbit anti-CACHD1 with peroxidase 854 
anti-rabbit secondary antibody with (brown) DAB stain. CA1-3: cornus ammonis 1-3; DG: 855 
dentate gyrus.  856 
 857 
Figure 4. Characterisation of CACHD1 and its effects on CaV3.1 channel expression. 858 
HEK cells were transfected with empty vector (vector control, VC), CACHD1, Myc-859 
CACHD1, GFP-CaV3.1-HA alone or in combination, as shown in each panel. (A) HEK cell 860 
lysates were analysed by Western blotting (WB). An antibody to CACHD1 recognised a 861 
single protein similar to the predicted size for CACHD1, but also recognized a non-specific 862 
protein in all lysates. (B) Cell-surface proteins were biotinylated and pull downs analysed for 863 
CACHD1 and Na+/K+-ATPase (loading control). In control cells, no immunoreactive 864 
CACHD1 was detected, confirming antibody specificity. In CACHD1 expressing cells, 865 
immunoreactive CACHD1 was detected. In both cell types, immunoreactive Na+/K+-ATPase 866 
was detected. (C) Cell-surface proteins were biotinylated and pull downs analysed for GFP-867 
CaV3.1-HA (HA) and Na+/K+-ATPase (loading control). In control cells and cells only 868 
expressing CACHD1, no HA signals were detected, confirming antibody specificity. In cells 869 
expressing GFP-CaV3.1-HA, HA signals were readily detected. Quantification of the HA 870 
signals (normalised to Na+/K+-ATPase) revealed expression of CACHD1 increased signals 871 
for GFP-CaV3.1-HA at the cell-surface, *p<0.05. Na+/K+-ATPase signals were detected in all 872 
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cell types (D) Inputs of the biotin pull down assays were analysed by WB. Signals for HA 873 
were only detected in cells expressing GFP-CaV3.1-HA, signals for CACHD1 were only 874 
detected in cells expressing Myc-CACHD1 and signals for E-actin were detected in all cell 875 
types. All blots are representative of n≥3 experiments.  876 
 877 
Figure 5. CaV3.1 and CACHD1 are present at the cell-surface and are in close 878 
proximity. Live HEK cells expressing empty vector (vector control, VC), VC + Myc-879 
CACHD1, GFP-CaV3.1-HA + VC, Myc-CACHD1 + GFP-CaV3.1-HA or CLR•RAMP1 880 
(positive control) were incubated with antibodies to HA and Myc, washed and fixed. (A) 881 
Cells were then incubated with appropriate secondary antibodies and immunoreactive 882 
proteins localised by immunofluorescence and confocal microscopy. In HEK-VC cells, no 883 
signals for GFP, HA or Myc were detected indicating specificity of detection. HA signals 884 
(arrowheads) were only detected in cells expressing GFP-CaV3.1-HA (as determined by the 885 
GFP signal) and CLR•RAMP1. Similarly, Myc signals (yellow arrowheads) were only 886 
detected in cells expressing Myc-CACHD1 and CLR•RAMP1. Scale bar, 10 μm (B) After 887 
the proximity ligation assay, no signals were detected in cells expressing empty vector or in 888 
cells expressing only Myc-CACHD1 or GFP-CaV3.1-HA. In contrast, PLA signals were 889 
detected in cells expressing Myc-CACHD1 + GFP-CaV3.1-HA (arrows) and CLR•RAMP1 890 
(arrows). Single optical sections are shown except for the PLA panel (CLR•RAMP1 891 
excluded) where 5 optical sections are merged, two above and two below (0.5 μm 892 
increments) from the optical sections shown in the GFP/DAPI panel. Scale bar, 20 μm. All 893 
images are representative of n=3 experiments. Figure 5 is supported by analysis of cell-894 
surface CACHD1 construct expression studies (Fig. 5-1). 895 
 896 
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Figure 6. Effects of CACHD1 and D2G-1 on CaV3.1 channels 897 
CACHD1 significantly increased current density as shown by (A) representative current 898 
density traces at -25 mV and (B) I-V relationships, VH -90 mV (*p<0.05, **p<0.01, 899 
***p<0.001, two-way ANOVA with Bonferroni post-hoc test). D2G-1 had no significant 900 
effect on current density as shown by (A) representative current density traces at -25 mV and 901 
(C) I-V relationships, VH -90 mV. CACHD1, but not D2G-1, significantly increased maximal 902 
conductance (inset, p<0.05, one-way ANOVA with Bonferroni post-hoc test).  903 
 904 
Figure 7. Effects of CACHD1 and D2G-1 on CaV3.2 and CaV3.3 channels 905 
CACHD1 significantly increased current density as shown by representative current density 906 
traces at -20 mV for (A) CaV3.2 and (C) CaV3.3, and I-V relationships for (B) CaV3.2 and (D) 907 
CaV3.3; VH -90 mV (*p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with Bonferroni 908 
post-hoc test). D2G-1 had no effect on (E) CaV3.2 and (F) CaV3.3 I-V relationships, VH -90 909 
mV. Figure 7 is supported by analysis of effects of CACHD1 and  D2G-1 on CaV3 channel 910 
kinetic properties (Fig. 7-1). 911 
 912 
Figure 8. CACHD1 expression increases CaV3.1 gating currents and open probability 913 
(Po). 914 
Representative gating currents recorded from CaV3.1 (Aa) and CaV3.1 + CACHD1 (Ab) at 915 
the observed reversal potential. Expanded time scale illustrates the increase in area under the 916 
gating current for CACHD1 expressed cells. B)  Conductance vs gating current plot for 917 
multiple cells. Line represents linear regression to data points. The slopes (Gmax/Qmax) were 918 
significantly different (P=0.0004, least squares fits compared using extra sum of squares F 919 
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test; CaV3.1:  0.09 ± 0.003, n=10, and CaV3.1 + CACHD1: 0.14 ± 0.090, n=11). C) Plot 920 
showing the slopes (i.e relative Po) and S.E.M. for fits shown in B (***p<0.001).    921 
 922 
Figure 9. Effects of CACHD1 in hippocampal neurons 923 
(A) Co-labelling of hippocampal neurons with CACHD1 and mVenus. (B) CACHD1 924 
increased firing frequency of hippocampal neurons. (C) Example traces in response to 925 
depolarizing current injections steps of -20, 70 and 140 pA. (D) Summary data from separate 926 
experiments confirming CACHD1-mediated increased firing frequency and also showing that 927 
TTA-P2 (1 μM) reduced firing rates in CACHD1-expressing neurons, but not in controls. (E) 928 
Rebound APs were evoked using a -50 pA hyperpolarizing prepulse followed by a 929 
depolarizing step from 0 pA to 200 pA in steps of 10 pA for 200 ms, CACHD1 expressing 930 
neurons displayed a significantly greater number of rebound APs compared to controls. (F) 931 
Example traces representing depolarizing current injection steps of 40, 90 and 140 pA. (G) 932 
Summary data from separate experiments confirming CACHD1-mediated increased in 933 
rebound APs and also showing that TTA-P2 (1 μM) reduced firing rates in CACHD1-934 
expressing neurons, but not in controls. *P<0.05 throughout, two-tailed paired Student’s t-test 935 
or one-way ANOVA with Bonferroni post-hoc test. Figure 9 is supported by analysis of 936 
effects of CACHD1 and TTA-P2 on biophysical properties of hippocampal neurons (Fig. 9-937 
1). 938 
 939 
Extended Data Figure Legends 940 
 941 
Figure 1-1: CACHD1 mRNA expression in adult rat brain. 942 
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In situ hybridization of adult rat brain. CACHD1 mRNA was labelled pink with blue 943 
counterstain (Gill’s I Haematoxylin). CA1-3: cornus ammonis 1-3; DG: dentate gyrus; g: 944 
granule cell layer; m: molecular layer; p: Purkinje cell; wm: white matter.  945 
 946 
Figure 1-2: Qualitative expression profile of CACHD1 mRNA and protein in the adult 947 
rat brain.  948 
+ labelling similar to background; ++ weak labelling; +++ moderate labelling, ++++ strong 949 
labelling; +++++ very strong labelling. 950 
 951 
Figure 2-1: Expression profile of CACHD1 and voltage-gated calcium channel subunit 952 
mRNA in human tissue. 953 
Absolute quantification of CACHD1, D2G-1, -2, -3, CaV2.2 and CaV1, -2, -3 transcripts was 954 
assessed in triplicate by TaqMan® qPCR using ‘Best Coverage’ Taqman probes (Applied 955 
Biosystems, UK) against a 5-point standard curve of plasmids consisting of 10-fold dilution 956 
of a known copy number of plasmid containing cDNA of the gene of interest. Total RNA was 957 
extracted using an RNeasy kit (Qiagen, UK) with an on-column DNase I treatment. 958 
Additional total RNA samples from AMS Biotechnology (Abingdon, UK) originated from 959 
human male donors aged 24-65.  960 
 961 
Figure 5-1:Analysis of cell-surface CACHD1 construct expression.  962 
(A, B) HEK cells were transfected with empty vector (vector control, VC) or Myc-CACHD1 963 
and cell lysates analysed by (A) Western blotting (WB) and (B) immunofluorescence and 964 
confocal microscopy. (A) Immunoreactive signals for Myc (mouse Myc, mMyc) were 965 
detected at a similar molecular mass to that predicted for CACHD1 only in cells expressing 966 
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CACHD1. (B, upper panel) Cells were incubated with antibody to Myc (rabbit Myc, rMyc), 967 
washed, fixed and then incubated with appropriate secondary antibodies. Myc signals 968 
(arrowheads) were only detected in cells expressing Myc-CACHD1. (B, lower panel) Cells 969 
were fixed, incubated with antibody to Myc (rMyc), washed and then incubated with 970 
appropriate secondary antibodies. Myc signals were detected at the cell-surface (arrowheads) 971 
and in intracellular vesicles only in cells expressing Myc-CACHD1. Scale bar, 10 μm.  972 
 973 
Figure 7-1: Effects of CACHD1 and D2G-1 on CaV3 channel kinetic properties 974 
CACHD1 co-expression had no significant effect on tactivation in (Aa) CaV3.1, (Ba) CaV3.2 and 975 
(Ca) CaV3.3. D2G-1 significantly increased CaV3.1 tactivation at all voltages tested (Aa) 976 
(*p<0.05, **p<0.01, ***p<0.001, two-way ANOVA with Bonferroni post-hoc test); D2G-1 977 
had no effect on CaV3.2 tactivation (Ba); D2G-1 significantly decreased CaV3.3 tactivation at -35 978 
and -30 mV (Ca) (*p<0.05, ***p<0.001, two-way ANOVA with Bonferroni post-hoc test). 979 
CACHD1 co-expression had no significant effect on tinactivation in (Ab) CaV3.1, (Bb) CaV3.2 980 
and (Cb) CaV3.3. D2G-1 co-expression with CaV3.1 (Ab) resulted in significantly faster 981 
inactivation kinetics (*p<0.05, one-way ANOVA with Bonferroni post-hoc test), but had no 982 
effect on tinactivation in (Bb) CaV3.2 and (Cb) CaV3.3. Inactivation traces at -20 mV or -30 mV 983 
were fitted with a single exponential function. 984 
 985 
Figure 9-1: Effects of CACHD1 and TTA-P2 on biophysical properties of hippocampal 986 
neurons.  987 
Extended Data Fig. 9-1 supports Figure 9. 988 
 989 
  990 
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Table 1. Effects of CACHD1 and α2δ-1 on biophysical properties of CaV3 subtypes. 991 
 
Gmax 
(pS/pF) 
V1/2 
(mV) 
k 
(mV) 
τ activation 
(ms)* 
τ 
inactivation 
(ms)** 
CaV3.1 (18) 628 ± 70 
-34.5 ± 0.8 
(30) 
5.4 ± 0.1 
(30) 2.0 ± 0.1  25.8 ± 2.0  
CaV3.1/ 
CACHD1 (19) 944 ± 90* 
-36.3 ± 0.9 
(29) 
5.6 ± 0.2 
(29) 2.0 ± 0.2  22.2 ± 4.8  
CaV3.1/ 
α2δ-1 (13) 672 ± 90 -35.7 ± 1.4 5.6 ± 0.3 3.3 ± 0.2
ΔΔ 18.9 ± 0.86Δ 
*=p<0.05 vs. CaV3.1 (one-way ANOVA with Bonferroni post-hoc test) 
Δ =p<0.05, ΔΔ =p<0.05 vs. CaV3.1 (two-way ANOVA with Bonferroni post-hoc test) 
 
CaV3.2 (13) 596 ± 120 -34.4 ± 2.4 5.7 ± 0.2 7.1 ± 0.40 33.3 ± 0.97 
CaV3.2/ 
CACHD1 (15) 1060 ± 140* -33.4 ± 0.8 5.9 ± 0.2 5.9 ± 0.38 32.0 ± 1.6 
*=p<0.05 vs. CaV3.2 (two-tailed unpaired Student’s t-test) 
 
CaV3.3 (12) 573 ± 88 -36.1 ± 1.2 4.3 ± 0.2 24.4 ± 1.9 134 ± 12 
CaV3.3/ 
CACHD1 (10) 849 ± 78* -38.9 ± 1.6 4.0 ± 0.3 28.5 ± 3.4 126 ± 8.3 
*=p<0.05 vs. CaV3.3 (two-tailed unpaired Student’s t-test) 
 992 
In all cases, comparisons were performed in culture-matched experiments. Numbers in 993 
parenthesis represents number of cells each from a minimum of 5 separate transfections. 994 
 995 
* τ activation was measured at -25 mV in all cases.  996 
** τ inactivation was measured at -20 mV for CaV3.1 and CaV3.2 and at -30 mV for CaV3.3. 997 
998 
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 Table 2. Effects of CACHD1 and TTA-P2 on hippocampal neuronal firing 999 
 1000 
 Firing frequency 
(Hz) 
Rebound firing frequency 
(Hz) 
Control  6.0 ± 1.2 (41/6) 7.2 ± 1.2 (32/5) 
CACHD1 9.8 ± 1.1* (29/5) 12.1 ± 0.9* (28/5) 
   
Control  8.5 ± 1.4 (6/3) 10.0 ± 1.8 (6/3) 
Control + TTA-P2  6.5 ± 1.2 (6/3) 9.2 ± 1.5 (6/3) 
   
CACHD1  14.1 ± 1.7 (7/3) 16.7 ± 0.8 (10/3) 
CACHD1  
+ TTA-P2 6.9 ± 1.4* (7/3) 10.0 ± 1.2* (10/3) 
*= p<0.05 vs control two-tailed paired Student’s t-test  
Values represent means ± S.E.M; number in parenthesis = number of neurons/number 
of separate transfections. 
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